SENIOR VICE PRESIDENT OF CELGENE GLOBAL HEALTH AND GLOBAL MEDICAL AFFAIRS, CELGENE
Dr. Joseph S. Camardo, M.D., is a Member of the American College of Physicians Foundation and currently serves as Senior Vice President-Global Medical Affairs and Global Health at Celgene Corp. Dr. Camardo is also on the Board of Directors at ScripsAmerica, Inc., Mali Health Organizing Project and Rosemont College. Prior to Celgene, Dr. Camardo worked at several leading pharmaceuticals companies, including Forest Laboratories, Pfizer and Wyeth, where he held senior positions in medical affairs. He received his B.A., majoring in Biology from the University of Pennsylvania and a doctorate degree in Internal Medicine from Perelman School of Medicine, University of Pennsylvania.
FORMER VICE PRESIDENT OF CLINICAL DEVELOPMENT AT CELGENE AND NOVARTIS
Dr. Christian Jacques, M.D., is co-founder and Chief Scientific Officer at Pharma Biotech Consultants, LLC. Previously, Dr. Jacques served as Vice President-Clinical Development at Celgene, during which he was in charge of multiple myeloma clinical developments at Celgene. Dr. Jacques also held multiple roles at Novartis, Johnson & Johnson and Sanofi prior to Celgene. Dr. Jacques is a hematologist oncologist by background and he trained for both his M.D. degree and his Internal Medicine degree at the Catholic University of Louvain, Belgium. Dr. Jacques has also been a hospital practitioner for 10 years.
GLOBAL HEAD OF ONCOLOGY, PAREXEL
Dr. Denis Miller, M.D. currently serves as Global Therapeutics Area Leader-Hematology and Oncology at Parexel. Prior to joining Parexel, Dr. Miller held multiple positions in pharmaceutical R&D and clinical oncology at Hoffmann-La Roche and Johnson & Johnson, as well as clinical research organizations. He has served in leadership roles at premier cancer centers, medical centers and hospitals including as Chairman, Department of Pediatrics at Memorial Sloan Kettering Cancer Center. Dr. Miller holds B.A. and M.D. degrees from Cornell University, and was a Fulbright Scholar at the University of London, Saint Mary's Hospital Medical School. He completed his post-graduate residency and fellowship training at the Children's Hospital Medical Center and Harvard Medical School, and is Board Certified in pediatrics and pediatric hematology/oncology.
HEAD, METABOLISM & CANCER SUSCEPTIBILITY SECTION OF NATIONAL CANCER INSTITUTE
Dr. James Phang, M.D. is chief of the Endocrinology Section at National Cancer Institute. Dr. Phang was a senior investigator in the Metabolism Branch, NCI. From 1989 to 1998, he served as chief of the Laboratory of Nutritional and Molecular Regulation, and in 1998, he formed the Metabolism and Cancer Susceptibility Section in the Basic Research Laboratory. The Section joined the Laboratory of Comparative Carcinogenesis in 2003. Dr. Phang received his M.D. from Loma Linda University School of Medicine and completed his training in internal medicine from Stanford Medical Center.
Director，Liver cancer research，Massachusetts General Hospital Cancer Center
Dr. Andrew X. Zhu is Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma through phase I, II and III clinical trials. The second area of his research interests is directed at the development of novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area of his research is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma and assess their potential correlation with clinical outcomes and as therapeutic targets.
As a widely published author, Dr. Zhu has served as a principle investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. He is the invited reviewer for many medical journals and has lectured extensively on HCC and other gastrointestinal cancers. An internationally recognized leader in HCC and cholangiocarcinoma, he has led early efforts of developing several molecularly targeted agents in liver cancers and studying the predictive and surrogate circulating and imaging biomarkers. He is a founding board member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research. Dr. Zhu serves on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, and the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee (GISC). He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.